Introduction. Chemical structure of etanercept, pharmacokinetics and mechanism of action;Introducción. Estructura química de etanercept, farmacocinética y mecanismo de acción

Actas Dermo-Sifiliograficas

Volumn 101, Issue SUPPL. 1, 2010, Pages 1-4

  Dauden E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Anti TNF; Biological therapy; Etanercept; Psoriasis; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CHEMICAL STRUCTURE; DRUG MECHANISM; HUMAN; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY;

HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952529471     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(10)70001-6     Document Type: Article

References (6)

1. M. Lebwohl Psoriasis Lancet 361 2003 1197 1204
2. M.P. Schön, and W.H. Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
3. W.H. Boehncke, J. Prinz, and A.B. Gottlieb Biologic therapies for psoriasis. A systematic review J Rheumatol 33 2006 1447 1451
4. J.L. López Estebaranz Etanercept. Estructura química, farmacocinética y mecanismo de acción Actas Dermosifiliogr 96 Suppl 3 2005 2 9
5. I. Nestorov Clinical pharmacokinetics of tumor necrosis factor antagonists J Rheumatol 32 Suppl 74 2005 13 18
6. G. Spencer-Green Etanercept (Enbrel): update on therapeutic use Ann Rheum Dis 59 Suppl 1 2000 46 49